NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
BioXcel Therapeutics, Inc. BTAI
9 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$642,000
▼ 71.7% vs FY2024
EPS · FY25
$-5.73
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-10887.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 642,000.00
Revenue, FY2025 · full 9-year series below
Revenue
Net income
The company lost 10887 cents on every revenue dollar this year.
Per share
USD -5.73
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-7860.0%
Net margin-10887.4%
Return on assets-167.9%
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+19.6%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.02B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 44.9M
total assets, end of FY2025
Total assetsUSD 44.9M
EquityUSD -95.5M
CashUSD 28.4M
Gross debtUSD 109.6M
Net debtUSD 81.2M
Current ratio0.83×
Net debt stands at -85% of equity.
History
9 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
Revenue $B
0.0
0.0
0.0
0.0
·
·
·
·
·
Operating income $B
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
·
·
·
·
·
·
Net income $B
−0.1
−0.1
−0.2
−0.2
−0.1
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−5.73
−23.51
−98.33
−5.92
−4.05
−3.79
−2.02
−1.32
−0.47
Dividend / sh $
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
ROE %
·
·
−1766.9
−111.1
−49.9
−70.4
−100.2
−101.7
·
Shares out B
0.02
0.00
0.00
0.03
0.03
0.02
0.02
0.02
0.01
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
27 of 27
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed